Oura eyes a $2.2 billion IPO on the Nasdaq, balancing rapid revenue growth and strategic partnerships with medical device firms against ongoing regulatory scrutiny and class-action litigation.
Oura is seeking to raise up to $2.2B in an IPO on Nasdaq under ticker OURA, with shares priced at $40-44.
Oura has partnered with Dexcom, which makes continuous glucose monitors.
Oura has partnered with Resmed, which makes devices to treat sleep apnea.
Wearables manufacturer Oura has filed for an initial public offering, seeking to raise up to $2.2 billion with shares priced between $40 and $44. The company plans to list on the Nasdaq under the ticker OURA as it navigates the regulatory boundary between consumer wellness devices and FDA-cleared medical technology.
Oura manufactures smart rings that track activity, sleep, and stress metrics, generating revenue through both device sales and recurring membership subscriptions.
Currently, Oura's features fall under the FDA's wellness exemption; however, the company is developing advanced health features that may require formal FDA clearance in the future.